The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome.
Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome.
Coupe
M O
MO
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Anderson
J V
JV
Morris
J A
JA
Alstead
E M
EM
Bloom
S R
SR
Hodgson
H J
HJ
D000328:Adult; D000368:Aged; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000150:complications*; D008875:Middle Aged; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000077526:Tropisetron
D007211:Indoles; D012702:Serotonin Antagonists; D000077526:Tropisetron